Candel Therapeutics, Inc. CADL Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s stock-based comp?
- Candel Therapeutics, Inc. (CADL) reported stock-based comp of $1.45M in Q1 2026.
- How has Candel Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Candel Therapeutics, Inc.'s stock-based comp increased by 362.4% year-over-year, from $314K to $1.45M.
- What is the long-term trend for Candel Therapeutics, Inc.'s stock-based comp?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s stock-based comp has grown at a 18.3% compound annual growth rate (CAGR), from $2.31M to $3.82M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.